SPARC had out-licensed XELPROS to Sun Pharma in June 2015 and this commercialisation of XELPROS, has triggered a milestone payment of USD 10 Million and sales linked royalties, by Sun Pharma to SPARC.
›
▸
Link: https://scores.gov.in